Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model

BACKGROUND: 3-bromopyruvate (3-BrPA) is a glycolytic inhibitor that affects cancer cells by targeting energy metabolism. Preclinical reports have established that a 1.75 mM dose of 3-BrPA is effective and sufficient to inhibit tumor growth when administered under a loco-regional approach (intraarter...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kunjithapatham, Rani, Geschwind, Jean-Francois H, Rao, Pramod P, Boronina, Tatiana N, Cole, Robert N, Ganapathy-Kanniappan, Shanmugasundaram
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2013
Pynciau:
Short Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3728150/
https://ncbi.nlm.nih.gov/pubmed/23866825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-6-277
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg